medical conditions allergies to any of the components used in the formulation of the bamlanivimab hospitalization or expected to need hospitalization in the next 24 hours at the time of recruitment for covid-19 suspected or proven infection other than covid-19 that in the opinion of the clinicians could pose a risk to study inclusion any co-morbidity considered life-threatening in <28 days, or requiring surgery in <7 days. any serious disease, condition or disorder that in the opinion of the clinicians should preclude participation. require oxygen therapy due to covid-19 require an increase in baseline oxygen flow rate due to covid-19 in those on chronic oxygen therapy due to underlying non-covid-19 related comorbidity. weighs < 40 kg history of vaccination against sars-cov2 history of convalescent plasma or ivig therapy within 3 months of first sars-cov2 viral determination positive history of previous sars-cov2 infection history of participation in any clinical study involving an investigational intervention within 30 days or 5 half-lives of the previous intervention, whichever is longer. unable to achieve informed consent for any reason known pregnancy actively breast-feeding.

medical conditions allergies to any of the components used in the formulation of the bamlanivimab hospitalization or expected to need hospitalization in the next 24 hours at the time of recruitment for covid-19 suspected or proven infection other than covid-19 that in the opinion of the clinicians could pose a risk to study inclusion any co-morbidity considered life-threatening in <28 days, or requiring surgery in <7 days. any serious disease, condition or disorder that in the opinion of the clinicians should preclude participation. require oxygen therapy due to covid-19 require an increase in baseline oxygen flow rate due to covid-19 in those on chronic oxygen therapy due to underlying non-covid-19 related comorbidity. weighs < 40 kg history of vaccination against sars-cov2 history of convalescent plasma or ivig therapy within 3 months of first sars-cov2 viral determination positive history of previous sars-cov2 infection history of participation in any clinical study involving an investigational intervention within 30 days or 5 half-lives of the previous intervention, whichever is longer. unable to achieve informed consent for any reason known pregnancy actively breast-feeding.

1. medical conditions 1. allergies to any of the components used in the formulation of the bamlanivimab 2. hospitalization or expected to need hospitalization in the next 24 hours at the time of recruitment for covid-19 3. suspected or proven infection other than covid-19 that in the opinion of the clinicians could pose a risk to study inclusion 4. any co-morbidity considered life-threatening in <28 days, or requiring surgery in <7 days. 5. any serious disease, condition or disorder that in the opinion of the clinicians should preclude participation. 6. require oxygen therapy due to covid-19 7. require an increase in baseline oxygen flow rate due to covid-19 in those on chronic oxygen therapy due to underlying non-covid-19 related comorbidity. 2. weighs < 40 kg 3. history of vaccination against sars-cov2 4. history of convalescent plasma or ivig therapy within 3 months of first sars-cov2 viral determination positive 5. history of previous sars-cov2 infection 6. history of participation in any clinical study involving an investigational intervention within 30 days or 5 half-lives of the previous intervention, whichever is longer. 7. unable to achieve informed consent for any reason 8. known pregnancy 9. actively breast-feeding.

1. medical conditions 1. allergies to any of the components used in the formulation of the bamlanivimab 2. hospitalization or expected to need hospitalization in the next 24 hours at the time of recruitment for covid-19 3. suspected or proven infection other than covid-19 that in the opinion of the clinicians could pose a risk to study inclusion 4. any co-morbidity considered life-threatening in <28 days, or requiring surgery in <7 days. 5. any serious disease, condition or disorder that in the opinion of the clinicians should preclude participation. 6. require oxygen therapy due to covid-19 7. require an increase in baseline oxygen flow rate due to covid-19 in those on chronic oxygen therapy due to underlying non-covid-19 related comorbidity. 2. weighs < 40 kg 3. history of vaccination against sars-cov2 4. history of convalescent plasma or ivig therapy within 3 months of first sars-cov2 viral determination positive 5. history of previous sars-cov2 infection 6. history of participation in any clinical study involving an investigational intervention within 30 days or 5 half-lives of the previous intervention, whichever is longer. 7. unable to achieve informed consent for any reason 8. known pregnancy 9. actively breast-feeding.

1. medical conditions 1. allergies to any of the components used in the formulation of the bamlanivimab 2. hospitalization or expected to need hospitalization in the next 24 hours at the time of recruitment for covid-19 3. suspected or proven infection other than covid-19 that in the opinion of the clinicians could pose a risk to study inclusion 4. any co-morbidity considered life-threatening in <28 days, or requiring surgery in <7 days. 5. any serious disease, condition or disorder that in the opinion of the clinicians should preclude participation. 6. require oxygen therapy due to covid-19 7. require an increase in baseline oxygen flow rate due to covid-19 in those on chronic oxygen therapy due to underlying non-covid-19 related comorbidity. 2. weighs < 40 kg 3. history of vaccination against sars-cov2 4. history of convalescent plasma or ivig therapy within 3 months of first sars-cov2 viral determination positive 5. history of previous sars-cov2 infection 6. history of participation in any clinical study involving an investigational intervention within 30 days or 5 half-lives of the previous intervention, whichever is longer. 7. unable to achieve informed consent for any reason

1. medical conditions 1. allergies to any of the components used in the formulation of the bamlanivimab 2. hospitalization or expected to need hospitalization in the next 24 hours at the time of recruitment for covid-19 3. suspected or proven infection other than covid-19 that in the opinion of the clinicians could pose a risk to study inclusion 4. any co-morbidity considered life-threatening in <28 days, or requiring surgery in <7 days. 5. any serious disease, condition or disorder that in the opinion of the clinicians should preclude participation. 6. require oxygen therapy due to covid-19 7. require an increase in baseline oxygen flow rate due to covid-19 in those on chronic oxygen therapy due to underlying non-covid-19 related comorbidity. 2. weighs < 40 kg 3. history of vaccination against sars-cov2 4. history of convalescent plasma or ivig therapy within 3 months of first sars-cov2 viral determination positive 5. history of previous sars-cov2 infection 6. history of participation in any clinical study involving an investigational intervention within 30 days or 5 half-lives of the previous intervention, whichever is longer. 7. unable to achieve informed consent for any reason